Gradalis Emerges from Stealth With Phase II Cancer Vaccine
By Trista Morrison
Thursday, March 15, 2012
Cancer vaccines, long the red-headed stepchildren of biotech, were briefly catapulted into the limelight by Dendreon Corp.'s 2010 approval of Provenge (sipuleucel-T) only to be dragged back down by that drug's disappointing sales.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.